New drug combo trial offers hope for Hard-to-Treat prostate cancer

NCT ID NCT06785636

First seen Nov 17, 2025 · Last updated May 11, 2026 · Updated 29 times

Summary

This study tests a new drug called pocenbrodib, either by itself or combined with other treatments, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if it helps shrink tumors or lower PSA levels. About 252 adults with metastatic castration-resistant prostate cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer and Blood Research Center

    RECRUITING

    Los Alamitos, California, 90720, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46250, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Duke University medical center

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact

    Contact Phone: •••-•••-••••

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Johns Hopkins Hospital

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MemorialCare Orange Coast Medical Center

    RECRUITING

    Fountain Valley, California, 92708, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mount Sinai Medical Center

    RECRUITING

    Miami, Florida, 33140, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology - Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-••••

    Contact

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact Phone: •••-•••-••••

    Contact

  • Ochsner

    RECRUITING

    Jefferson, Louisiana, 70121, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Oncology Consultants, P.A

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

    Contact

  • Siteman Cancer Center

    RECRUITING

    St Louis, Missouri, 63108, United States

    Contact Phone: •••-•••-••••

    Contact

  • Taylor Cancer Research Center

    RECRUITING

    Maumee, Ohio, 43537, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Colorado Health

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.